Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined...

por Leone, A.G., Petrelli, F., Ghidini, A., Raimondi, A., Smyth, E.C., Pietrantonio, F.
Publicado 2022

Predictive role of microsatellite instability for of PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials

por Pietrantonio, F., Randon, G., Di Bartolomeo, M., Luciani, A., Chao, J., Smyth, E.C., Petrelli, F.
Publicado 2021

Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology

por Leone, A.G., Miceli, R., Trapani, D., Massagrande, M., Morano, F., Marsoni, S., La Verde, N., Berardi, R., Casolino, R., Lambertini, M., Dalu, D., Di Maio, M., Beretta, G.D., Perrone, F., Cinieri, S., Pietrantonio, F.
Publicado 2023

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by...

por Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., Marmorino, F., Zaniboni, A., Buonadonna, A., Masi, G., Lonardi, S., Pietrantonio, F., Falcone, A., Antonuzzo, A., Cremolini, C.
Publicado 2021

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of...

por Raimondi, A., Fucà, G., Leone, A.G., Lonardi, S., Antoniotti, C., Smiroldo, V., Amatu, A., Tampellini, M., Ritorto, G., Murialdo, R., Clavarezza, M., Zaniboni, A., Berenato, R., Ratti, M., Corallo, S., Morano, F., Di Bartolomeo, M., Di Maio, M., Pietrantonio, F.
Publicado 2021

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type ci...

por Martini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., Del Re, M., Lonardi, S., Aprile, G., Santini, D., Masi, G., Avallone, A., Normanno, N., Pietrantonio, F., Pinto, C., Ciardiello, F., Cremolini, C., Martinelli, E.
Publicado 2023

Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study

por Borelli, B., Fontana, E., Giordano, M., Antoniotti, C., Lonardi, S., Bergamo, F., Pietrantonio, F., Morano, F., Tamburini, E., Boccaccino, A., Santini, D., Zucchelli, G., Pella, N., Maiello, E., Passardi, A., Zaniboni, A., Ugolini, C., Fontanini, G., Falcone, A., Nyamundanda, G., Sadanandam, A., Cremolini, C.
Publicado 2021

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysi...

por Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., Santini, D.
Publicado 2022

Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial

por Grassi, E., Zingaretti, C., Petracci, E., Corbelli, J., Papiani, G., Banchelli, I., Valli, I., Frassineti, G.L., Passardi, A., Di Bartolomeo, M., Pietrantonio, F., Gelsomino, F., Carandina, I., Banzi, M., Martella, L., Bonetti, A.V., Boccaccino, A., Molinari, C., Marisi, G., Ugolini, G., Nanni, O., Tamberi, S.
Publicado 2023